7.18
Wave Life Sciences Ltd (WVE) 最新ニュース
Wave Life Sciences to present WVE-006 trial data at ATS - Investing.com
Pictet Asset Management Holding SA Purchases 790,175 Shares of WAVE Life Sciences Ltd. $WVE - MarketBeat
A Look At Wave Life Sciences (WVE) Valuation After Q1 2026 Results And RNA Pipeline Progress - simplywall.st
WAVE Life Sciences (NASDAQ:WVE) Upgraded to "Hold" at Wall Street Zen - MarketBeat
WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Wave Life Sciences (NASDAQ: WVE) proposes one‑for‑one redomiciliation to Delaware - Stock Titan
Wave Life Sciences 2025 Executive Compensation, Governance, and Business Highlights – 10-K/A Report - Minichart
MSN Money - MSN
Canaccord lowers Wave Life Sciences stock price target on valuation By Investing.com - Investing.com India
WVE Maintained by Canaccord Genuity -- Price Target Lowered to $43.00 - GuruFocus
Wave Life Sciences Signals Momentum In Earnings Call - The Globe and Mail
Wave Life Sciences : Amendment to Annual Report (Form 10-K/A) - marketscreener.com
Wave Life Sciences (Nasdaq: WVE) details 2025 milestones, cash and executive pay - Stock Titan
Wave Life Sciences Ltd. (NASDAQ:WVE) Q1 2026 Earnings Call Transcript - Insider Monkey
B. Riley Securities Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $31 - Moomoo
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $15 to $43 - Moomoo
Canaccord lowers Wave Life Sciences stock price target on valuation - Investing.com
WVE SEC FilingsWave Life Scienc 10-K, 10-Q, 8-K Forms - Stock Titan
Does Strong Q1 2026 Beat and Narrower Loss Reshape The Bull Case For Wave Life Sciences (WVE)? - simplywall.st
Duchenne Muscular Dystrophy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Vertex Pharma, Bioleaders Corp., Wave Life Sciences, REGENXBIO - Barchart.com
RBC Capital Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $15 - Moomoo
WAVE Life Sciences (NASDAQ:WVE) Shares Down 7.6%Here's What Happened - MarketBeat
B. Riley Securities Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $31 - Moomoo
WAVE Life Sciences (NASDAQ:WVE) Posts Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
WVE Maintained by Truist Securities -- Price Target Lowered to $15 - GuruFocus
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $15 to $36 - Moomoo
Truist Financial Initiates Wave Life Sciences(WVE.US) With Buy Rating, Announces Target Price $15 - Moomoo
Wave Life Sciences Ltd. Q1 2026 Earnings Call Summary - Yahoo Finance
Wave Life Sciences: Q1 Earnings Snapshot - theheraldreview.com
Truist assumes coverage on Wave Life Sciences stock with buy rating - Investing.com India
WAVE Life Sciences Ltd (WVE) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Advancements - GuruFocus
WAVE Life Sciences Q1 2026 Earnings Call Transcript - MarketBeat
Wave Life Sciences (WVE) Q1 Revenue Surge Tests Bearish Profitability Concerns - simplywall.st
Clear Street Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
RBC Capital reiterates Wave Life Sciences stock rating on obesity pipeline progress By Investing.com - Investing.com South Africa
RBC Capital reiterates Wave Life Sciences stock rating on obesity pipeline progress - Investing.com Canada
WAVE Life Sciences Q1 Earnings Call Highlights - MarketBeat
Wave (WVE) Q1 2025 Earnings Call Transcript - The Motley Fool
WAVE Life Sciences (NASDAQ:WVE) Trading 5.5% HigherTime to Buy? - MarketBeat
BofA cuts Wave Life Sciences stock price target on trial focus - Investing.com
Is WAVE Life Sciences (WVE) Overvalued After Q1 2026 8-K? GF Sco - GuruFocus
BofA cuts Wave Life Sciences stock price target on trial focus By Investing.com - Investing.com India
Clear Street cuts Wave Life Sciences stock price target on obesity trial outlook - Investing.com Canada
Earnings call transcript: Wave Life Sciences Q1 2026 beats EPS forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Wave Life Sciences Q1 2026 beats EPS forecast - Investing.com
Wave Life Sciences Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Wave Life Sciences (WVE) Reports Strong Q1 Revenue and Advances WVE-007 Development - GuruFocus
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update - Investing News Network
Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Wave Life Sciences 1Q Research and Development Expenses $47.4M >WVE - Moomoo
Q1 2026 WAVE Life Sciences Ltd Earnings Call Transcript - GuruFocus
Wave Life Sciences (NASDAQ:WVE) Beats Q1 Estimates as Obesity Program Accelerates - ChartMill
Wave Life Sciences Reports Q1 Results, Advances RNA Pipeline - TipRanks
WAVE LIFE SCIENCES ($WVE) Releases Q1 2026 Earnings - Quiver Quantitative
Wave Life Sciences (WVE) lifts Q1 revenue, trims loss with strong cash runway - Stock Titan
大文字化:
|
ボリューム (24 時間):